Hemispherx Adds Two New CFS Trial Sites Philadelphia (ots-PRNewswire) - Hemispherx Biopharma, Inc. (Amex: HEB) today announced that it completed contractual arrangements with two new sites that will begin enrolling patients in a confirmatory Phase III clinical trial of the drug Ampligen(R) in the treatment of Chronic Fatigue Syndrome (CFS) that has been authorized by the Food and Drug Administration. The company said that it has contracted with a total of 15 sites at major CFS treatment centers across the U.S. to participate in one or more of the company's drug development programs for CFS. The sites are located in the states of New York, New Jersey, California, Illinois, Pennsylvania, North Carolina, Virginia, Florida, Utah, Nevada and Alabama. Eight of these sites are participating in the Phase III clinical trials, while the others are participating in the open-label treatment protocol. Hemispherx said that patients who have been enrolled in the current Phase III clinical trials and who have completed required baseline evaluations at previously announced sites have begun treatment. Under the protocol authorized by the Food and Drug Administration, the confirmatory Phase III trial includes a multi-week baseline period in which patients are evaluated quantitatively for physical and cognitive performance. After this period, patients are selected at random to receive either a placebo or Ampligen(R). The treatment is double-blinded, meaning that neither the physicians nor the patients are aware of which patients are receiving the placebo or the drug until after the trial is completed. To the company's knowledge, Hemispherx is the only company with authorized Phase III studies in the U.S. for CFS and the only company with a pending application for full marketing approval in the European Union. The Center for Disease Control (CDC) estimates that CFS affects approximately 500,000 Americans and various medical studies suggest a similar number of Europeans are affected as well. Hemispherx Biopharma, which is based in Philadelphia, is a pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including CFS, hepatitis B and hepatitis C. Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. ots Original Text Service: Hemispherx Biopharma, Inc. Internet: http://www.newsaktuell.de Contact: William A. Carter, M.D., CEO and Chairman of Hemispherx Biopharma (USA) 215-988-0080 William J. Jenks, Media (USA) 212-232-2222, fax, (USA) 212-232-3232, or Sharon Will, Investor Relations (USA) 212-572-0762, fax, (USA) 212-572-0764 of Broadgate for Hemispherx Web site: http://www.hemispherx.com e-mail: NA_global@newsaktuell.de

Klíčová slova

Praha, Česká republika (ce)


Přihlásit k odběru

Materiály označené značkou Protext nejsou součástí zpravodajského servisu ČTK a nelze je publikovat pod její značkou. Jde o komerční sdělení zadavatele, který je ve zprávě označen a který za ně nese plnou odpovědnost.